Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

CXCR3+ monocytes/macrophages are required for establishment of pulmonary metastases.

Butler KL, Clancy-Thompson E, Mullins DW.

Sci Rep. 2017 Mar 30;7:45593. doi: 10.1038/srep45593.

2.

Integrative analysis of breast cancer reveals prognostic haematopoietic activity and patient-specific immune response profiles.

Varn FS, Andrews EH, Mullins DW, Cheng C.

Nat Commun. 2016 Jan 4;7:10248. doi: 10.1038/ncomms10248.

3.

Site-Specific Immunomodulator: A Novel Treatment for Crohn's Disease.

Bressler B, Bethel KP, Kleef R, Reynolds SL, Sutcliffe S, Mullins DW, Gunn H.

Gastroenterol Res Pract. 2015;2015:231243. doi: 10.1155/2015/231243. Epub 2015 May 12.

4.

Melanoma Induces, and Adenosine Suppresses, CXCR3-Cognate Chemokine Production and T-cell Infiltration of Lungs Bearing Metastatic-like Disease.

Clancy-Thompson E, Perekslis TJ, Croteau W, Alexander MP, Chabanet TB, Turk MJ, Huang YH, Mullins DW.

Cancer Immunol Res. 2015 Aug;3(8):956-67. doi: 10.1158/2326-6066.CIR-15-0015. Epub 2015 Jun 5.

5.

The BRAF(V600E) inhibitor, PLX4032, increases type I collagen synthesis in melanoma cells.

Jenkins MH, Croteau W, Mullins DW, Brinckerhoff CE.

Matrix Biol. 2015 Oct;48:66-77. doi: 10.1016/j.matbio.2015.05.007. Epub 2015 May 16.

6.

CXCR3 signaling in BRAFWT melanoma increases IL-8 expression and tumorigenicity.

Jenkins MH, Brinckerhoff CE, Mullins DW.

PLoS One. 2015 Mar 23;10(3):e0121140. doi: 10.1371/journal.pone.0121140. eCollection 2015.

7.

BRAF inhibition alleviates immune suppression in murine autochthonous melanoma.

Steinberg SM, Zhang P, Malik BT, Boni A, Shabaneh TB, Byrne KT, Mullins DW, Brinckerhoff CE, Ernstoff MS, Bosenberg MW, Turk MJ.

Cancer Immunol Res. 2014 Nov;2(11):1044-50. doi: 10.1158/2326-6066.CIR-14-0074. Epub 2014 Sep 2.

8.

Multiple murine BRaf(V600E) melanoma cell lines with sensitivity to PLX4032.

Jenkins MH, Steinberg SM, Alexander MP, Fisher JL, Ernstoff MS, Turk MJ, Mullins DW, Brinckerhoff CE.

Pigment Cell Melanoma Res. 2014 May;27(3):495-501. doi: 10.1111/pcmr.12220. Epub 2014 Mar 6. No abstract available.

9.

Peptide vaccination in Montanide adjuvant induces and GM-CSF increases CXCR3 and cutaneous lymphocyte antigen expression by tumor antigen-specific CD8 T cells.

Clancy-Thompson E, King LK, Nunnley LD, Mullins IM, Slingluff CL Jr, Mullins DW.

Cancer Immunol Res. 2013 Nov;1(5):332-9. doi: 10.1158/2326-6066.CIR-13-0084.

10.

Differential expression and tumor necrosis factor-mediated regulation of TNFRSF11b/osteoprotegerin production by human melanomas.

Oliver JL, Alexander MP, Norrod AG, Mullins IM, Mullins DW.

Pigment Cell Melanoma Res. 2013 Jul;26(4):571-9. doi: 10.1111/pcmr.12091. Epub 2013 Apr 11.

11.

Immune-mediated regression of established B16F10 melanoma by intratumoral injection of attenuated Toxoplasma gondii protects against rechallenge.

Baird JR, Byrne KT, Lizotte PH, Toraya-Brown S, Scarlett UK, Alexander MP, Sheen MR, Fox BA, Bzik DJ, Bosenberg M, Mullins DW, Turk MJ, Fiering S.

J Immunol. 2013 Jan 1;190(1):469-78. doi: 10.4049/jimmunol.1201209. Epub 2012 Dec 7.

12.

Differential mechanisms of tumor progression in clones from a single heterogeneous human melanoma.

Croteau W, Jenkins MH, Ye S, Mullins DW, Brinckerhoff CE.

J Cell Physiol. 2013 Apr;228(4):773-80. doi: 10.1002/jcp.24225.

13.

Extracellular hepatitis C virus core protein activates STAT3 in human monocytes/macrophages/dendritic cells via an IL-6 autocrine pathway.

Tacke RS, Tosello-Trampont A, Nguyen V, Mullins DW, Hahn YS.

J Biol Chem. 2011 Mar 25;286(12):10847-55. doi: 10.1074/jbc.M110.217653. Epub 2011 Jan 31.

14.

The protein tyrosine phosphatase SHP-1 modulates the suppressive activity of regulatory T cells.

Iype T, Sankarshanan M, Mauldin IS, Mullins DW, Lorenz U.

J Immunol. 2010 Nov 15;185(10):6115-27. doi: 10.4049/jimmunol.1000622. Epub 2010 Oct 15.

15.

Interferons induce CXCR3-cognate chemokine production by human metastatic melanoma.

Dengel LT, Norrod AG, Gregory BL, Clancy-Thompson E, Burdick MD, Strieter RM, Slingluff CL Jr, Mullins DW.

J Immunother. 2010 Nov-Dec;33(9):965-74. doi: 10.1097/CJI.0b013e3181fb045d.

Supplemental Content

Loading ...
Support Center